Collection
Early access to medicines scheme (EAMS): scientific opinions
Information on granted EAMS scientific opinions, including the public assessment report and treatment protocols.
Current EAMS
-
Early access to medicines scheme (EAMS) scientific opinion: Nivolumab to treat advanced or recurrent gastric or gastroesophageal junction cancer after two or more systemic therapies
- Decision
-
Early access to medicines scheme (EAMS) scientific opinion: Raxone to treat the decline of respiratory function in patients with Duchenne Muscular Dystrophy
- Decision
-
Early access to medicines scheme (EAMS) scientific opinion: Volanesorsen as a treatment of adult patients with familial chylomicronaemia syndrome
- Decision
Published 3 June 2015
Last updated 20 March 2018 + show all updates
Last updated 20 March 2018 + show all updates
- Early Access to Medicines Scientific Opinion on Volanesorsen to treat adult patients with familial chylomicronaemia syndrome
- Amended to add the positive scientific opinion for emicizumab for routine prophylaxis of bleeding episodes in patients, aged 1 year and over, with haemophilia A with factor VIII inhibitors
- Added Nivolumab to treat advanced or recurrent gastric or gastroesophageal junction cancer after two or more systemic therapies to current EAMS opinions.
- Removed Dupilumab (for severe atopic dermatitis) from current EAMS as this product received a marketing authorisation from the European Commission.
- Link to the EAMS Scientific Opinion for Alectinib has been added to the page.
- New EAMS scientific opinion for Raxone added to the collections page.
- New EAMS scientific opinion for Oxervate added to the page.
- Added EAMS scientific opinion: Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (HCV) infection in adults
- EAMS for Dupilumab published
- SO for pembrolizumab for non-small cell lung cancer removed from current EAMS list.
- New EAMS positive scientific opinion
- Nivolumab to treat a type of cancer of the Lymph system - the Scientific Opinion has now expired due to a positive EC decision
- Added link to the scientific opinion: venetoclax for the treatment of chronic lymphocytic leukaemia (CLL)
- Added: Early access to medicines scheme (EAMS) scientific opinion: osimertinib (AZD9291) 40 and 80mg film-coated tablets
- New EAM issued to Novartis for sacubitril-valsartan
- First published.